~~<i id='700252A507'><strike id='700252A507'><tt id='700252A507'><pre id='700252A507'></pre></tt></strike></i>~~

Home» explore» leisure time

leisure time

author：hotspot 2025-09-29 02:58:47 Page View：7

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Why you shouldn’t ask, “What country has the best health care?”
Next article： ChatGPT in medicine: STAT answers readers' burning questions

focus

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

Why doctors need education on FDA device approval process

AdobeInherfinalpresentationforhealthpolicyclassattheUniversityofChicago,first-yearmedicalstudentRobi